RecruitingNot ApplicableNCT06937814

The Effect of Humiome® Post LB on Gut COMFort in healthY Adult Volunteers

The Effect of Humiome® Post LB on Gut COMFort in healthY Adult Volunteers: a Double-blind, Randomized Placebo-controlled Study


Sponsor

dsm-firmenich Switzerland AG

Enrollment

250 participants

Start Date

Jun 16, 2025

Study Type

INTERVENTIONAL

Conditions

Summary

The goal of this double-blind, randomized placebo-controlled study is to evaluate the effect of an 8-week supplementation of Humiome ® Post LB (170 mg) on bowel movements in healthy adult volunteers compared to Placebo adjusted on baseline. The main question\[s\] it aims to answer \[is/are\]: Does Humiome ® Post LB improve bowel movements with self-reported GI issues? Participants will be provided Humiome ® Post LB (170 mg) for 8 weeks and asked to complete a study diary, questionnaires, and stool samples.


Eligibility

Min Age: 18 YearsMax Age: 75 Years

Plain Language Summary

Simplified for easier understanding

This clinical trial is studying Humiome ® Post LB and Placebo for people with bowel movements, gi issues, and other related conditions. The study is currently recruiting participants at 1 location.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.

Interventions

DIETARY_SUPPLEMENTHumiome ® Post LB

Participants will be instructed to take one capsule with a glass of water after the first meal of the day.

OTHERPlacebo

Participants will be instructed to take one capsule with a glass of water after the first meal of the day.


Locations(1)

KGK Science Inc.

London, Ontario, Canada

View Full Details on ClinicalTrials.gov

For the most up-to-date information, visit the official listing.

Visit

NCT06937814


Related Trials